<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        170-186-02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CEFUZIME 250MG TAB.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFUROXIME AXETIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        41.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Cefuzime </strong>is an antibiotic used in adults and children. It works by killing bacteria that cause infections. It belongs to a group of medicines called cephalosporins.</p><p><strong>Cefuzime</strong> is used to treat infections of:</p><p>&middot; the throat</p><p>&middot; sinus</p><p>&middot; middle ear</p><p>&middot; the lungs or chest</p><p>&middot; the urinary tract</p><p>&middot; the skin and soft tissues.</p><p><strong>Cefuzime can also be used: </strong></p><p>&middot; to treat Lyme disease (an infection spread by parasites called ticks).</p><p>Your doctor may test the type of bacteria causing your infection and monitor whether the bacteria are sensitive to <strong>Cefuzime </strong>during your treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>Don&rsquo;t take Cefuzime : </strong></p><p>&middot; <strong>if you are allergic</strong> to <strong>any</strong> <strong>cephalosporin antibiotics</strong> or any of the other ingredients of <strong>Cefuzime </strong>&nbsp;(listed in section 6).</p><p>&middot; if you have ever had a severe allergic (hypersensitive) reaction to any other type of betalactam antibiotic (penicillins, monobactams and carbapenems).</p><p>If you think this applies to you, <strong>don&rsquo;t take Cefuzime </strong>until you have checked with your doctor.</p><p><strong>Take special care with Cefuzime &nbsp;</strong></p><p><strong>Cefuzime is not recommended for children aged less than 3 months</strong>, as the safety and effectiveness are not known in this age group.</p><p>You must look out for certain symptoms, such as allergic reactions, fungal infections (such as <em>candida</em>) and severe diahorrea (<em>pseudomembranous colitis</em>) while you are taking <strong>Cefuzime</strong>. This will reduce the risk of any problems. See &lsquo;Conditions you need to look out for&rsquo; in Section 4.<strong> </strong></p><p><strong>If you need a blood test </strong></p><p><strong>Cefuzime </strong>can affect the results of a test for blood sugar levels, or a blood screen called the <em>Coombs test</em>.</p><p>If you need a blood test: <strong>Tell the person taking the sample </strong>that you are taking <strong>Cefuzime. </strong></p><p><strong>Other medicines and Cefuzime &nbsp;</strong></p><p>Tell your doctor or pharmacist if you are taking any other medicines, if you&rsquo;ve started taking any recently or you start taking new ones. This includes medicines you can obtain without a prescription.</p><p>&middot; Medicines used to <strong>reduce the amount of acid in your stomach</strong> (e.g. <em>antacids </em>used to treat <strong>heartburn</strong>) can affect how <strong>Cefuzime </strong>works.</p><p>&middot; Probenecid</p><p>&middot; Oral anticoagulants</p><p><strong>Tell your doctor or pharmacist if </strong>you are taking any medicine like this.<strong> </strong></p><p><strong>Contraceptive pills </strong></p><p><strong>Cefuzime </strong>may reduce the effectiveness of the contraceptive pill. If you are taking the contraceptive pill while you are being treated with <strong>Cefuzime </strong>you also need to use a <strong>barrier method of contraception</strong> (such as condoms). Ask your doctor for<strong> </strong>advice<strong>.</strong></p><p><strong>Pregnancy and breast-feeding and fertility </strong></p><p>Tell your doctor before you take <strong>Cefuzime</strong>:</p><p>&middot; if you are pregnant, think you might be pregnant or are planning to become pregnant</p><p>&middot; if you are breastfeeding.</p><p>Your doctor will consider the benefit of treating you with <strong>Cefuzime </strong>against the risk to your baby.</p><p><strong>Driving and using machines </strong></p><p><strong>Cefuzime can make you dizzy </strong>and have other side effects that make you less alert.<strong> </strong></p><p><strong>Don&rsquo;t drive or use machines</strong> if you do not feel well</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take this medicine exactly as your doctor or pharmacist has told you to</strong>. Check with your doctor or pharmacist if you are not sure.</p><p><strong>Take Cefuzime after food</strong>. This will help to make the treatment more effective.</p><p>Swallow <strong>Cefuzime </strong>tablets whole with some water.</p><p><strong>Don&#39;t chew, crush or split the tablets &mdash; </strong>this may make the treatment less effective.<strong> </strong></p><p><strong>The usual dose </strong></p><p><strong>Adults </strong></p><p>The usual dose of <strong>Cefuzime</strong> is 250 mg to 500 mg twice daily depending on the severity and type of infection.</p><p><strong>Children </strong></p><p>The usual dose of <strong>Cefuzime </strong>is 10 mg/kg (to a maximum of 125 mg) to 15 mg/kg (to a maximum of 250 mg) twice daily depending on:</p><p>&middot; the severity and type of infection</p><p><strong>Cefuzime is not recommended for children aged less than 3 months</strong>, as the safety and effectiveness are not known in this age group.</p><p>Depending on the illness or how you or your child responds to treatment, the initial dose may be changed or more than one course of treatment may be needed.</p><p><strong>Patients with kidney problems </strong></p><p>If you have a kidney problem, your doctor may change your dose.</p><p><strong>Talk to your doctor</strong> if this applies to you.</p><p><strong>If you take too much Cefuzime &nbsp;</strong></p><p>If you take too much <strong>Cefuzime </strong>you may have neurological disorders, in particular you may be more likely to have fits <em>(seizures). </em></p><p>Don&#39;t delay. Contact your doctor or your nearest hospital emergency department immediately. If possible, show them the <strong>Cefuzime </strong>pack.</p><p><strong>If you forget to take Cefuzime &nbsp;</strong></p><p>Don&#39;t take an extra dose to make up for a missed dose. Just take your next dose at the usual time.</p><p><strong>Don&rsquo;t stop Cefuzime without advice </strong></p><p><strong>It is important that you take the full course of Cefuzime. </strong>Don&rsquo;t stop unless your doctor advises you to &ndash; even if you are feeling better. If you don&#39;t complete the full course of treatment, the infection may come back.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 1.</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Conditions you need to look out for </strong></p><p>A small number of people taking <strong>Cefuzime </strong>get an allergic reaction or potentially serious skin reaction. Symptoms of these reactions include:</p><p>&middot; <strong>severe allergic reaction</strong>. Signs include <strong>raised and itchy rash</strong>, <strong>swelling</strong>, sometimes of the face or mouth causing <strong>difficulty in breathing.</strong></p><p>&middot; <strong>skin rash</strong>, which may <strong>blister</strong>, and looks like <strong>small</strong> <strong>targets</strong> (central dark spot surrounded by a paler area, with a dark ring around the edge).</p><p>&middot; <strong>a widespread rash</strong> with <strong>blisters</strong> <strong>and peeling skin</strong>. (These may be signs of Stevens-Johnson syndrome or toxic epidermal necrolysis).</p><p><strong>Other conditions you need to look out for while taking Cefuzime include: </strong></p><p>&middot; <strong>fungal infections</strong>. Medicines like <strong>Cefuzime </strong>can cause an overgrowth of yeast (Candida) in the body which can lead to fungal infections (such as thrush). This side effect is more likely if you take <strong>Cefuzime </strong>for a long time.</p><p>&middot; <strong>Severe diarrhoea (Pseudomembranous colitis).</strong> Medicines like <strong>Cefuzime </strong>&nbsp;can cause inflammation of the colon (large intestine), causing severe diarrhoea, usually with blood and mucus, stomach pain, fever</p><p>&middot; <strong>Jarisch-Herxheimer reaction.</strong> Some patients may get a high temperature (fever), chills, headache, muscle pain and skin rash while being treated with <strong>Cefuzime </strong>for Lyme disease. This is known as the Jarisch-Herxheimer reaction. Symptoms usually last a few hours or up to one day.</p><p><strong>Contact a doctor or nurse immediately if you get any of these symptoms.</strong></p><p><strong>Common side effects </strong></p><p>These may affect <strong>up to 1 in 10</strong> people:</p><p>&middot; fungal infections (such as Candida)</p><p>&middot; headache</p><p>&middot; dizziness</p><p>&middot; diarrhoea</p><p>&middot; feeling sick</p><p>&middot; stomach pain.</p><p>Common side effects that may show up in blood tests:</p><p>&middot; an increase in a type of white blood cell (eosinophilia)</p><p>&middot; an increase in liver enzymes.</p><p><strong>Uncommon side effects </strong></p><p>These may affect <strong>up to 1 in 100</strong> people:</p><p>&middot; being sick</p><p>&middot; skin rashes.</p><p>Uncommon side effects that may show up in blood tests:</p><p>&middot; a decrease in the number of blood platelets (cells that help blood to clot)</p><p>&middot; a decrease in the number of white blood cells</p><p>&middot; positive Coomb&rsquo;s test.</p><p><strong>Other side effects </strong></p><p>Other side effects have occurred in a very small number of people, but their exact frequency is unknown:</p><p>&middot; severe diarrhoea (pseudomembranous colitis)</p><p>&middot; allergic reactions</p><p>&middot; skin reactions (including severe)</p><p>&middot; high temperature (fever)</p><p>&middot; yellowing of the whites of the eyes or skin</p><p>&middot; inflammation of the liver (hepatitis).</p><p>Side effects that may show up in blood tests:</p><p>&middot; red blood cells destroyed too quickly (haemolytic anaemia).</p><p><strong>If you get any side effects, tell your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. </strong></p><p>&nbsp;</p><p><strong><u>To report any side effect(s): </u></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax:</strong> +966-11-205-7662</p><p><strong>Call NPC at</strong> +966-11-2038222,</p><p><strong>Exts:</strong> 2317-2356-2353-2354-2334-2340.</p><p><strong>Toll free phone:</strong> 8002490000</p><p><strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>Website:</strong> www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot; Keep out of the reach and sight of children.</p><p>&middot; Do not use <strong>Cefuzime </strong>after the expiry date which is stated on the carton and the blister.</p><p>&middot; Store below 30<sup>o</sup>C, in a dry place.</p><p>&middot; Do not use <strong>Cefuzime </strong>if you notice any visible sign of deterioration.</p><p>&middot; Medicines should<em> </em>not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Cefuroxime. Each film coated-tablet contains 125mg, 250mg or 500mg of Cefuroxime (as Cefuroxime axetil).</p><p>&nbsp; The other ingredients: Sodium lauryl sulphate, croscarmellose, kollidon, Microcrystalline cellulose, aerosil, Primojel, cross linked starch, polyethylene glycol, hypromellose, titanium dioxide, and talc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Cefuzime film-coated tablets are available in packs of 10 tablets each.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
17/11/2015

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>سيفوزيم</strong> هو عبارة عن مضاد حيوي يستخدم لدى البالغين والأطفال. يعمل عن طريق القضاء على البكتيريا المسببة للعدوى. والذي ينتمي إلى مجموعة من الأدوية تعرف باسم السيفالوسبورينات.</p><p><strong>يستخدم </strong><strong>سيفوزيم لعلاج &nbsp;حالات عدوى:</strong></p><p>&middot; الحلق</p><p>&middot; الجيوب الأنفية</p><p>&middot; الأذن الوسطى</p><p>&middot; الرئتين أو الصدر</p><p>&middot; الجهاز البولي</p><p>&middot; الجلد أو النسيج الرخو</p><p><strong>من الممكن أن يستخدم </strong><strong>سيفوزيم أيضاً في:</strong></p><p><strong>&middot; </strong>علاج مرض لايم (عدوى تنتشر عن طريق الطفيليات وتعرف باسم داء القراد)</p><p>قد يقوم طبيبك المعالج باجراء فحصاً طبياً لمعرفة نوع البكتيريا المسببة للعدوى، ومراقبة البكتيريا ما إذا كانت حساسة تجاه <strong>سيفوزيم </strong>أثناء فترة العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>يجب عليك عدم تناول سيفوزيم في الحالات التالية:</strong></p><p>&middot; <strong>إذا كنت تعاني من الحساسية</strong> تجاه <strong>أي من المضادات الحيوية من مجموعة السيفالوسبورينات</strong> أو تجاه المواد الأخرى الموجودة في <strong>سيفوزيم</strong> (المذكورة في بند 6).</p><p>&middot; إذا كنت قد عانيت سابقاً من تفاعلات تحسسية شديدة (فرط الحساسية) تجاه أي نوع من مضادات حيوية من مجموعة بيتا لاكتام (بنسيلينات، مونوباكتام وكاربابيمينات).</p><p>إذا كنت تعتقد أن مما ذكر أعلاه ينطبق عليك،<strong> فيجب عليك عدم تناول سيفوزيم </strong>إلى أن تستشير طبيبك المعالج بذلك.</p><p><strong>رعاية خاصة مع سيفوزيم</strong></p><p><strong>لا يوصى بتناول سيفوزيم من قبل الأطفال بعمر أقل من 3 سنوات</strong>، حيث أن سلامة وفعالية هذا الدواء لهذه الفئة العمرية غير معروفة.</p><p>يجب أن تنتبه لبعض الأعراض الجانبية في أثناء تناول <strong>سيفوزيم</strong>، على سبيل المثال التفاعلات التحسسية، عدوى فطرية (على سبيل المثال كانديدا) ، إسهال شديد (التهاب القولون الغشائي الكاذب).</p><p>سوف يساعد هذا الإجراء على تقليل الخطورة من أية مشاكل. انظر &quot;الحالات التي يجب أن تكون على دراية بها&quot; في بند 4.</p><p><strong>إذا كنت بحاجة لإجراء فحص الدم </strong></p><p>من الممكن أن يؤثر <strong>سيفوزيم </strong>على نتائج فحص مستويات السكر في الدم أو فحص الدم الذي يعرف باسم فحص كومب.</p><p>إذا كنت بحاجة لإجراء فحص للدم: <strong>يرجى منك إخبار الشخص الذي سوف يأخذ العينة منك </strong>بأنك تتناول <strong>سيفوزيم.</strong></p><p><strong>تناول الأدوية الأخرى مع سيفوزيم</strong></p><p>يرجى منك إخبار طبيبك المعالج &nbsp;أو الصيدلي الذي تتعامل معه إذا كنت تتناول أية أدوية أخرى، إذا كنت قد بدأت بتناول أي أدوية قد تناولتها مؤخراً أو أدوية جديدة. بما في ذلك الأدوية التي يتم صرفها بدون وصفة طبية.</p><p>&middot; من الممكن أن تؤثر الأدوية التي تستخدم <strong>للحد من كمية الحمض في المعدة</strong> (على سبيل المثال مضادات الحموضة التي تستخدم لعلاج <strong>حرقة المعدة</strong>) على آلية عمل <strong>سيفوزيم</strong>.</p><p>&middot; البروبنيسيد</p><p>&middot; مضادات التخثر الفموية</p><p><strong>يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه</strong> إذا كنت تتناول أي من مضادات التخثر الفموية.</p><p><strong>&nbsp;</strong><strong>حبوب منع الحمل</strong></p><p>قد يقلل <strong>سيفوزيم</strong> من فعالية حبوب منع الحمل. إذا كنت تتناولين حبوب منع الحمل في أثناء علاجك مع <strong>سيفوزيم</strong> فقد تحتاجين بأن تستخدمي <strong>إحدى طرق الأغشية الحاجزة لمنع الحمل</strong> (على سبيل المثال الواقي الذكري). يرجى منك استشارة الطبيب المعالج لطلب النصيحة.</p><p><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p>يرجى منك إخبار طبيبك المعالج قبل تناول <strong>سيفوزيم</strong>:</p><p>&middot; إذا كنت حاملاً، &nbsp;تعتقدين أنك حاملاً أو تخططين لأن تصبحين حاملاً</p><p>&middot; إذا كنت ترضعين طفلك رضاعة طبيعية</p><p>سوف يقارن طبيبك المعالج ما بين الفائدة المرجوة من العلاج مع <strong>سيفوزيم </strong>والمخاطر المحتمل حدوثها والتي سوف يتعرض لها الطفل.</p><p><strong>القيادة وتشغيل الآلات</strong></p><p><strong>قد يؤدي سيفوزيم إلى الشعر بالدوخة </strong>والمعاناة من تأثيرات جانبية أخرى والتي تجعلك أقل تركيزاً.</p><p><strong>يجب عدم القيادة أو تشغيل الآلات</strong> ما لم تكن تشعر بأنك بحالة جيدة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>احرص دائماً على تناول هذا الدواء بدقة وفقاً لارشادات طبيبك المعالج أو الصيدلي الذي تتعامل معه. </strong>يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه ما لم تكن متأكداً من كيفية تناول <strong>سيفوزيم</strong>.</p><p><strong>يرجى تناول سيفوزيم بعد وجبة الطعام</strong> . الأمر الذي يساعد على جعل هذا العلاج أكثر فعالية.</p><p>يجب عليك بلع أقراص <strong>سيفوزيم </strong>بالكامل مع بعضاً من الماء.</p><p><strong>يجب عدم مضغ، سحق أو تقسيم الأقراص-</strong> حيث أن مضغ أو سحق الأقراص قد<strong> </strong>يجعل العلاج أقل فعالية.</p><p><strong>الجرعة الاعتيادية</strong></p><p><strong>البالغون</strong></p><p>يتراوح مقدار الجرعة الاعتيادية من <strong>سيفوزيم </strong>ما بين 250 ملغم إلى 500 ملغم مرتين يومياً اعتماداً على شدة ونوع العدوى.</p><p><strong>الأطفال</strong></p><p>يبلغ مقدار الجرعة الاعتيادية من <strong>سيفوزيم </strong>10 ملغم/كغم (إلى أقصى جرعة بمقدار 125 ملغم) إلى 15ملغم/كغم (إلى أقصى جرعة بمقدار 250 ملغم) مرتين يومياً اعتماداً على:</p><p>&middot; شدة ونوع العدوى</p><p><strong>لا يوصى بتناول سيفوزيم من قبل الأطفال بعمر أقل من 3 سنوات</strong>، حيث أن سلامة وفعالية هذا الدواء لهذه الفئة العمرية غير معروفة.</p><p>قد تتغير الجرعة الابتدائية أو قد يحتاج إلى أكثر من دورة علاج واحدة، اعتماداً على طبيعة المرض ومدى استجابتك أو استجابة طفلك للعلاج .</p><p><strong>المرضى الذين يعانون من مشاكل في الكلى</strong></p><p>قد يرغب طبيبك المعالج بتغير مقدارالجرعة، إذا كنت تعاني من مشاكل في الكلى.</p><p><strong>يرجى منك التحدث مع طبيبك المعالج</strong> إذا كنت تعاني من مشاكل في الكلى.</p><p><strong>إذا تناولت العديد من أقراص </strong><strong>سيفوزيم</strong></p><p>قد تعاني من اضطرابات عصبية إذا تناولت العديد من أقراص <strong>سيفوزيم</strong>، وبصورة خاصة قد تكون أكثرعرضة للإصابة بنوبات الصرع (تشنجات).</p><p>يرجى منك التواصل مع طبيبك المعالج أو التوجه إلى قسم الطوارئ في أقرب مستشفى على الفور. ويجب عليك عدم تأجيل ذلك. مع أخذ عبوة <strong>سيفوزيم </strong>معك، إذا كان ذلك ممكناً.</p><p><strong>إذا سهوت عن تناول سيفوزيم </strong></p><p>يجب عدم تناول جرعة إضافية لتعويض الجرعة التي سهوت عنها. يجب عليك فقط تناول الجرعة التالية في الوقت المعتاد.</p><p><strong>يجب عدم التوقف عن تناول سيفوزيم ما لم ينصحك الطبيب بذلك.</strong></p><p><strong>من </strong><strong>الضروري اتمام دورة العلاج بصورة كاملة </strong><strong>&nbsp;</strong><strong>دورة باستخدام سيفوزيم</strong>، يجب عليك عدم التوقف عن تناول هذا الدواء إلا إذا نصحك طبيبك المعالج بذلك &ndash; حتى وإن شعرت بتحسن. إذا لم تنهي دورة العلاج كاملة، فمن الممكن معاودة تكرار حدوث العدوى.</p><p><strong>يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن جميع الأدوية، قد يسبب هذا الدواء تأثيرات جانبية، ولكن على الرغم من ذلك قد لا تحدث لكل شخص.</p><p><strong>الحالات التي يجب أن تكون على دراية بها</strong></p><p>هناك عدد قليل من االأشخاص الذين يتناولون <strong>سيفوزيم </strong>تعرضوا للاصابة بتفاعلات تحسسية أو تفاعلات جلدية والتي قد تكون خطيرة. أعراض هذه التفاعلات تتضمن على:</p><p><strong>&middot; </strong><strong>تفاعلات تحسسية حادة</strong>. تتضمن العلامات على <strong>طفح جلدي بارز ومصحوب بحكة</strong>، <strong>تورم</strong>، وبعض الأحيان في الوجه أو الفم مسببه <strong>صعوبة في التنفس</strong></p><p><strong>&middot; </strong><strong>طفح جلدي</strong>، الذي قد يظهر على شكل <strong>بثور</strong> (بقعة داكنة في الوسط محاطة بمنطقة شاحبة اللون، مع حلقة داكنة حول الحافة).</p><p><strong>&middot; </strong><strong>طفح جلدي </strong><strong>منتشر</strong> على نطاق واسع مع ظهور <strong>بثور جلدية</strong> <strong>وتقشر الجلد</strong>. (قد تكون علامات لمتلازمة ستفين جونسون أو انحلال البشرة السمي التنخري)</p><p><strong>الحالات الأخرى التي يجب أن تكون على دراية بها أثناء تناول سيفوزيم</strong></p><p><strong>&middot; </strong><strong>العدوى الفطرية</strong>. من الممكن أن تسبب الأدوية على سبيل المثال <strong>سيفوزيم</strong> فرط نمو الخميرة (كانديدا) في الجسم مما قد يؤدي إلى حدوث العدوى الفطرية (على سبيل المثال داء القلاع). تزيد احتمالية حدوث هذا التأثير الجانبي عند استعمال <strong>سيفوزيم</strong> لفترة زمنية طويلة.</p><p><strong>&middot; </strong><strong>إسهال شديد (</strong><strong>التهاب القولون الغشائي الكاذب)</strong>. من الممكن أن تسبب الأدوية على سبيل المثال <strong>سيفوزيم </strong>التهاب القولون (الأمعاء الغليظة)، تسبب إسهال شديد، عادة يكون مصحوب بظهور الدم والمخاط، ألم في المعدة، حمى</p><p><strong>&middot; </strong><strong>تفاعل ياريش هيكسهايمر</strong>. يصاب بعض المرضى بارتفاع درجة حرارة الجسم (حمى)، قشعريرة، صداع، ألم في العضلات وطفح جلدي أثناء تناول<strong> سيفوزيم </strong>لعلاج مرض لايم. وتلك الحالة تعرف بتفاعل ياريش هيكسهايمر. عادةً تستمر الأعراض لبضع ساعات أو إلى يوم واحد.</p><p><strong>يرجى منك ال</strong><strong>تواصل مع طبيبك المعالج أو الممرض على الفور إذا تعرضت لأي من تلك الأعراض.</strong></p><p><strong>التأثيرات الجانبية الشائعة</strong></p><p>قد تؤثرعلى ما قد <strong>يصل</strong> <strong>إلى شخص واحد من كل 10 </strong>أشخاص:</p><p><strong>&middot; </strong>العدوى الفطرية (على سبيل المثال كانديدا)</p><p><strong>&middot; </strong>صداع</p><p><strong>&middot; </strong>دوخة</p><p><strong>&middot; </strong>إسهال</p><p><strong>&middot; </strong>شعور بالإعياء</p><p><strong>&middot; </strong>ألم في المعدة</p><p>التأثيرات الجانبية الشائعة التي قد تظهر في فحوصات الدم:</p><p><strong>&middot; </strong>ارتفاع نوع من أنواع خلايا الدم البيضاء (فرط الحمضيات)</p><p><strong>&middot; </strong>ارتفاع انزيمات الكبد.</p><p><strong>التأثيرات الجانبية الغير شائعة </strong></p><p>قد تؤثرعلى ما قد <strong>يصل إلى</strong> <strong>شخص واحد من كل 100</strong> شخص:</p><p><strong>&middot; </strong>توعك</p><p><strong>&middot; </strong>طفح جلدي</p><p>التأثيرات الجانبية الغير شائعة التي قد تظهر في فحوصات الدم:</p><p><strong>&middot; </strong>انخفاض تعداد الصفائح الدموية (الخلايا التي تساعد على تخثر الدم)</p><p><strong>&middot; </strong>انخفاض مستويات خلايا الدم البيضاء.</p><p><strong>&middot; </strong>نتائج إيجابية لفحص كومب.</p><p><strong>التأثيرات الجانبية الأخرى</strong></p><p>لقد حدثت التأثيرات الجانبية الأخرى لدى عدد قليل من الأشخاص، ولكن معدل تكرار حدوثها غير معروف:</p><p><strong>&middot; </strong>إسهال شديد (التهاب القولون الغشائي الكاذب).</p><p><strong>&middot; </strong>تفاعلات تحسسية</p><p><strong>&middot; </strong>تفاعلات جلدية (بما في ذلك التفاعلات الشديدة)</p><p><strong>&middot; </strong>ارتفاع درجة حرارة الجسم (حمى)</p><p><strong>&middot; </strong>اصفرار بياض العينين أو الجلد</p><p><strong>&middot; </strong>التهاب الكبد (الالتهاب الكبدي الوبائي)</p><p>التأثيرات الجانبية التي قد تظهر في فحوصات الدم:</p><p><strong>&middot; </strong>تحلل خلايا الدم بسرعة كبيرة (فقر الدم الانحلالي)</p><p><strong>يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه.</strong> <strong>إذا تعرضت لأياً من </strong><strong>تأثيرات جانبية بما في ذلك التأثيرات الجانبية المحتمل حدوثها ولم تذكر في هذه النشرة.</strong><strong> </strong></p><p><strong><u>للإبلاغ عن حدوث أية تأثيرات جانبية:</u></strong><br /><strong>&nbsp; المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p><strong>رقم الفاكس:</strong> 7662-205-11-966+</p><p><strong>يرجى الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية على: </strong>2038222-11-966+<strong>&nbsp; </strong></p><p><strong>وصلة هاتف:</strong>2340-2334-2354-2353-2356-23<strong>17</strong></p><p><strong>الهاتف المجاني: </strong>8002490000</p><p><strong>البريد الإلكتروني:</strong><strong> </strong>&nbsp;npc.drug@sfda.gov.sa</p><p><strong>الموقع الإلكتروني:</strong> www.sfda.gov.sa/npc</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&middot; </strong>يحفظ بعيداً عن متناول ومرأى الأطفال.</p><p><strong>&middot; </strong>&nbsp;يجب عدم تناول <strong>سيفوزيم</strong> بعد تاريخ انتهاء الصلاحية المذكور على العبوة&nbsp; والشريط .</p><p><strong>&middot; </strong>يحفظ في درجة حرارة أقل من 30&deg;م، في مكان جاف.</p><p><strong>&middot; </strong>يجب عدم تناول <strong>سيفوزيم</strong> إذا تم ملاحظة وجود علامات تلف واضحة.</p><p><strong>&middot; </strong>يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي سيفوروكسيم. يحتوي كل قرص مكسو على 125 ملغم، 250 ملغم أو 500 ملغم من سيفوروكسيم (على هيئة سيفوروكسيم أكستيل)</p><p>المواد الأخرى: لوريل كبريتات الصوديوم، كروس كارميلوز، كوليدون، بلورات السليلوز متناهية الصغر، ايروسيل، بريموجل، نشا كروس لنك، بولي اثيلين جلايكول، هيبروميللوز، ثنائي أكسيد التيتانيوم، تلك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            تتوفر أقراص سيفوزيم المكسوة في عبوات تحتوي  كل منها على 10 أقراص.
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&quot;الخليج للصناعات الدوائية &quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
17/11/2015

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cefuzime 250mg Film-Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains:
No.	Material Name	Scale (mg/Tablet)

1



1
2
3
4
5
6


1
2
3
4
5
6
	Active Ingredients:
Cefuroxime 
USE: Cefuroxime axetil

Inactive Ingredients:
Sodium lauryl sulfate                                   
Kollidon CL (Crospovidone)
Ac-Di-Sol (Croscarmellose Sodium)
Aerosil- 200 (Colloidal Silicon Dioxide)
Primojel (Sodium Starch Glycolate)
Avicel PH 302 (Microcrystalline Cellulose)

Coating Materials:
Hypromellose (Hydroxypropyl Methylcellulose)
Talc fine powder 
Titanium Dioxide
Polyethylene Glycol 4000
Ethanol 95*
Purified water*	
250.00
308.00


9.00
10.500
30.000
3.500
4.500
84.500


6.000
1.300
1.800
0.900
q.s.
q.s.
* Evaporates during processing and does not appear in the final product.

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-Coated Tablets
Description: White to off-white, oblong, parallel capsule shaped tablets.
Marking: Face one: Embossed with “250”
Face two: Plain.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Cefuzime</strong> is indicated for the treatment of the infections listed below in adults and children from the age of 3 months (see sections 4.4 and 5.1).</p><p>&middot;&nbsp;&nbsp; Acute streptococcal tonsillitis and pharyngitis.</p><p>&middot;&nbsp;&nbsp; Acute bacterial sinusitis.</p><p>&middot;&nbsp;&nbsp; Acute otitis media.</p><p>&middot;&nbsp;&nbsp; Acute exacerbations of chronic bronchitis.</p><p>&middot;&nbsp;&nbsp; Cystitis.</p><p>&middot;&nbsp;&nbsp; Pyelonephritis.</p><p>&middot;&nbsp;&nbsp; Uncomplicated skin and soft tissue infections.</p><p>&middot;&nbsp;&nbsp; Treatment of early Lyme disease.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p>The usual course of therapy is seven days (may range from five to ten days).</p><p><strong><em>Table 1: Adults and children (&ge;40 kg)</em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:660px"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Dosage</strong></p></td></tr><tr><td style="vertical-align:top"><p>Acute tonsillitis and pharyngitis, acute bacterial sinusitis</p></td><td style="vertical-align:top"><p>250 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Acute otitis media</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Acute exacerbations of chronic bronchitis</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Cystitis</p></td><td style="vertical-align:top"><p>250 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Pyelonephritis</p></td><td style="vertical-align:top"><p>250 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated skin and soft tissue infections</p></td><td style="vertical-align:top"><p>250 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Lyme disease</p></td><td style="vertical-align:top"><p>500 mg twice daily for 14 days (range of 10 to 21 days)</p></td></tr></tbody></table><p><strong><em>Table 2: Children (&lt;40 kg)</em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:660px"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Dosage</strong></p></td></tr><tr><td style="vertical-align:top"><p>Acute tonsillitis and pharyngitis, acute bacterial sinusitis</p></td><td style="vertical-align:top"><p>10 mg/kg twice daily to a maximum of 125 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Children aged two years or older with otitis media or, where appropriate, with more severe infections</p></td><td style="vertical-align:top"><p>15 mg/kg twice daily to a maximum of 250 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Cystitis</p></td><td style="vertical-align:top"><p>15 mg/kg twice daily to a maximum of 250 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Pyelonephritis</p></td><td style="vertical-align:top"><p>15 mg/kg twice daily to a maximum of 250 mg twice daily for 10 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated skin and soft tissue infections</p></td><td style="vertical-align:top"><p>15 mg/kg twice daily to a maximum of 250 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Lyme disease</p></td><td style="vertical-align:top"><p>15 mg/kg twice daily to a maximum of 250 mg twice daily for 14 days (10 to 21 days)</p></td></tr></tbody></table><p>There is no experience of using cefuroxime axetil in children under the age of 3 months.</p><p>Cefuroxime axetil tablets and cefuroxime axetil powder for oral suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis (see section 5.2).</p><p><strong><em>Renal impairment</em></strong></p><p>The safety and efficacy of cefuroxime axetil in patients with renal failure have not been established.</p><p>Cefuroxime is primarily excreted by the kidneys. In patients with markedly impaired renal function it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion. Cefuroxime is effectively removed by dialysis.</p><p><strong><em>Table 5: Recommended doses for Cefuroxime axetil in renal impairment</em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:670px"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine&nbsp;clearance</strong></p></td><td style="vertical-align:top"><p><strong>T<sub>&frac12;</sub>&nbsp;(hrs)</strong></p></td><td style="vertical-align:top"><p><strong>Recommended dosage</strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge;30 mL/min/1.73 m<sup>2</sup></p></td><td style="vertical-align:top"><p>1.4&ndash;2.4</p></td><td style="vertical-align:top"><p>no dose adjustment necessary (standard dose of 125 mg to 500 mg given twice daily)</p></td></tr><tr><td style="vertical-align:top"><p>10-29 mL/min/1.73 m<sup>2</sup></p></td><td style="vertical-align:top"><p>4.6</p></td><td style="vertical-align:top"><p>standard individual dose given every 24 hours</p></td></tr><tr><td style="vertical-align:top"><p>&lt;10 mL/min/1.73 m<sup>2</sup></p></td><td style="vertical-align:top"><p>16.8</p></td><td style="vertical-align:top"><p>standard individual dose given every 48 hours</p></td></tr><tr><td style="vertical-align:top"><p>Patients on haemodialysis</p></td><td style="vertical-align:top"><p>2&ndash;4</p></td><td style="vertical-align:top"><p>a further standard individual dose should be given at the end of each dialysis</p></td></tr></tbody></table><p><strong><em>Hepatic impairment</em></strong></p><p>There are no data available for patients with hepatic impairment. Since cefuroxime is primarily eliminated by the kidney, the presence of hepatic dysfunction is expected to have no effect on the pharmacokinetics of cefuroxime.</p><p><strong><u>Method of administration</u></strong></p><p>Oral use</p><p><strong>Cefuzime </strong>should be taken after food for optimum absorption.</p><p><strong>Cefuzime </strong>should not be crushed and are therefore unsuitable for treatment of patients who cannot swallow tablets. In children <strong>Cefuzime</strong> oral suspension may be used.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to cefuroxime or to any of the excipients listed in section 6.1.
•	Patients with known hypersensitivity to cephalosporin antibiotics.
•	History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of betalactam antibacterial agent (penicillins, monobactams and carbapenems).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Hypersensitivity reactions</u></strong></p><p>Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactam antibiotics because there is a risk of cross-sensitivity. As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefuroxime must be discontinued immediately and adequate emergency measures must be initiated.</p><p>Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefuroxime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if cefuroxime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.</p><p><strong><u>Jarisch-Herxheimer&nbsp;reaction</u></strong></p><p>The Jarisch-Herxheimer reaction has been seen following cefuroxime axetil treatment of Lyme disease. It results directly from the bactericidal activity of cefuroxime axetil on the causative bacteria of Lyme disease, the spirochaete&nbsp;<em>Borreliaburgdorferi.&nbsp;</em>Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease (see section 4.8).</p><p><strong><u>Overgrowth of non-susceptible microorganisms</u></strong></p><p>As with other antibiotics, use of cefuroxime axetil may result in the overgrowth of Candida. Prolonged use may also result in the overgrowth of other non-susceptible microorganisms (e.g. enterococci and&nbsp;<em>Clostridium difficile</em>), which may require interruption of treatment (see section 4.8).</p><p>Antibacterial agent&ndash;associated pseudomembranous colitis have been reported with nearly all antibacterial agents, including cefuroxime and may range in severity from mild to life threatening. This diagnosis should be considered in patients with diarrhoea during or subsequent to the administration of cefuroxime (see section 4.8). Discontinuation of therapy with cefuroxime and the administration of specific treatment for&nbsp;<em>Clostridium difficile</em>&nbsp;should be considered. Medicinal products that inhibit peristalsis should not be given (see section 4.8).</p><p><strong><u>Interference with diagnostic tests</u></strong></p><p>The development of a positive Coomb&#39;s Test associated with the use of cefuroxime may interfere with cross matching of blood (see section 4.8).</p><p>As a false negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving cefuroxime axetil.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Drugs which reduce gastric acidity may result in a lower bioavailability of cefuroxime axetil compared with that of the fasting state and tend to cancel the effect of enhanced absorption after food.</p><p>Cefuroxime axetil may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.</p><p>Cefuroxime is excreted by glomerular filtration and tubular secretion. Concomitant use of probenicid is not recommended. Concurrent administration of probenecid significantly increases the peak concentration, area under the serum concentration time curve and elimination half-life of cefuroxime.</p><p>Concomitant use with oral anticoagulants may give rise to increased INR.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>There are limited data from the use of cefuroxime in pregnant women. Studies in animals have shown no harmful effects on pregnancy, embryonal or foetal development, parturition or postnatal development. Cefuroxime axetil should be prescribed to pregnant women only if the benefit outweighs the risk.</p><p><strong><u>Breastfeeding</u></strong></p><p>Cefuroxime is excreted in human milk in small quantities. Adverse effects at therapeutic doses are not expected, although a risk of diarrhoea and fungus infection of the mucous membranes cannot be excluded. Breastfeeding might have to be discontinued due to these effects. The possibility of sensitisation should be taken into account. Cefuroxime should only be used during breastfeeding after benefit/risk assessment by the physician in charge.</p><p><strong><u>Fertility</u></strong></p><p>There are no data on the effects of cefuroxime axetil on fertility in humans. Reproductive studies in animals have shown no effects on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, as this medicine may cause dizziness, patients should be warned to be cautious when driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common adverse reactions are&nbsp;<em>Candida</em>&nbsp;overgrowth, eosinophilia, headache, dizziness, gastrointestinal disturbances and transient rise in liver enzymes.</p><p>The frequency categories assigned to the adverse reactions below are estimates, as for most reactions suitable data (for example from placebo-controlled studies) for calculating incidence were not available. In addition the incidence of adverse reactions associated with cefuroxime axetil may vary according to the indication.</p><p>Data from large clinical studies were used to determine the frequency of very common to rare undesirable effects. The frequencies assigned to all other undesirable effects (i.e. those occurring at &lt;1/10,000) were mainly determined using post-marketing data and refer to a reporting rate rather than true frequency. Placebo-controlled trial data were not available. Where incidences have been calculated from clinical trial data, these were based on drug-related (investigator assessed) data. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>Treatment related adverse reactions, all grades, are listed below by MedDRA body system organ class, frequency and grade of severity. The following convention has been utilised for the classification of frequency: very common &ge; 1/10; common &ge; 1/100 to &lt; 1/10, uncommon &ge; 1/1,000 to &lt; 1/100; rare &ge; 1/10,000 to &lt; 1/1,000; very rare &lt; 1/10,000 and not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:663px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p><em>Candida&nbsp;</em>overgrowth</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Clostridium difficile</em>overgrowth</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>eosinophilia</p></td><td style="vertical-align:top"><p>positive Coomb&#39;s test<sub>,</sub>thrombocytopenia, leukopenia (sometimes profound)</p></td><td style="vertical-align:top"><p>haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>drug fever, serum sickness, anaphylaxis, Jarisch-Herxheimer reaction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>headache, dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>diarrhoea, nausea, abdominal pain</p></td><td style="vertical-align:top"><p>vomiting</p></td><td style="vertical-align:top"><p>pseudomembranous colitis (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>transient increases of hepatic enzyme levels</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>jaundice (predominantly cholestatic), hepatitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>skin rashes</p></td><td style="vertical-align:top"><p>urticaria, pruritus, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (exanthematic necrolysis) (<em>see Immune system disorders</em>), angioneurotic oedema</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong><em>Description of selected adverse reactions</em></strong></p><p>Cephalosporins as a class tend to be absorbed onto the surface of red cells membranes and react with antibodies directed against the drug to produce a positive Coombs&#39; test (which can interfere with cross-matching of blood) and very rarely haemolytic anaemia.</p><p>Transient rises in serum liver enzymes have been observed which are usually reversible.</p></td></tr></tbody></table><p><strong><em>Paediatric&nbsp;population</em></strong></p><p>The safety profile for cefuroxime axetil in children is consistent with the profile in adults.</p><p>&nbsp;</p><p><strong><em><u>To report any side effect(s)</u></em></strong><strong><em><u>:</u></em></strong><strong><em><u> </u></em></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax:</strong> +966-11-205-7662</p><p><strong>Call NPC at</strong> +966-11-2038222, <strong>Exts:</strong> 2317-2356-2353-2354-2334-2340.</p><p><strong>Toll free phone:</strong> 8002490000</p><p><strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>Website:</strong> www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose can lead to neurological sequelae including encephalopathy, convulsions and coma. Symptoms of overdose can occur if the dose is not reduced appropriately in patients with renal impairment (see sections 4.2 and 4.4).</p><p>Serum levels of cefuroxime can be reduced by haemodialysis and peritoneal dialysis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> antibacterials for systemic use, second-generation cephalosporins, <strong>ATC code:</strong> J01DC02</p><p><strong><u>Mechanism of action</u></strong></p><p>Cefuroxime axetil undergoes hydrolysis by esterase enzymes to the active antibiotic, cefuroxime.</p><p>Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.</p><p><strong><u>Mechanism of resistance</u></strong></p><p>Bacterial resistance to cefuroxime may be due to one or more of the following mechanisms:</p><p>&bull;&nbsp;&nbsp; Hydrolysis by beta-lactamases; including (but not limited to) by extended-spectrum beta-lactamases (ESBLs), and AmpC enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacteria species;</p><p>&bull;&nbsp;&nbsp; Reduced affinity of penicillin-binding proteins for cefuroxime;</p><p>&bull;&nbsp;&nbsp; outer membrane impermeability, which restricts access of cefuroxime to penicillin binding proteins in Gram-negative bacteria;</p><p>&bull;&nbsp;&nbsp; Bacterial efflux pumps.</p><p>Organisms that have acquired resistance to other injectable cephalosporins are expected to be resistant to cefuroxime.</p><p>Depending on the mechanism of resistance, organisms with acquired resistance to penicillins may demonstrate reduced susceptibility or resistance to cefuroxime.</p><p><strong><u>Cefuroxime axetil breakpoints</u></strong></p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:663px"><tbody><tr><td style="vertical-align:top"><p><strong>Microorganism</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Breakpoints (mg/L)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>S</u></p></td><td style="vertical-align:top"><p><u>R</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em><sup>&nbsp;1, 2</sup></p></td><td style="vertical-align:top"><p>&le;8</p></td><td style="vertical-align:top"><p>&gt;8</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus</em>&nbsp;spp.</p></td><td style="vertical-align:top"><p>Note<sup>3</sup></p></td><td style="vertical-align:top"><p>Note<sup>3</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus&nbsp;</em>A, B, C and G</p></td><td style="vertical-align:top"><p>Note<sup>4</sup></p></td><td style="vertical-align:top"><p>Note<sup>4</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td><td style="vertical-align:top"><p>&le;0.25</p></td><td style="vertical-align:top"><p>&gt;0.5</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>&le;0.125</p></td><td style="vertical-align:top"><p>&gt;4</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td><td style="vertical-align:top"><p>&le;0.125</p></td><td style="vertical-align:top"><p>&gt;1</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints<sup>1</sup></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><sup>1&nbsp;</sup></strong>The cephalosporin breakpoints for&nbsp;<em>Enterobacteriaceae</em>&nbsp;will detect all clinically important resistance mechanisms (including ESBL and plasmid mediated AmpC). Some strains that produce beta-lactamases are susceptible or intermediate to 3rd or 4th generation cephalosporins with these breakpoints and should be reported as found, i.e. the presence or absence of an ESBL does not in itself influence the categorization of susceptibility. In many areas, ESBL detection and characterization is recommended or mandatory for infection control purposes.</p><p><sup>2&nbsp;</sup>Uncomplicated UTI (cystitis) only (see section 4.1).</p><p><sup>3</sup>&nbsp;Susceptibility of staphylococci to cephalosporins is inferred from the methicillin susceptibility except for ceftazidme and cefixime and ceftibuten, which do not have breakpoints and should not be used for staphylococcal infections.</p><p><sup>4</sup>&nbsp;The beta-lactam susceptability of beta-haemolytic streptococci groups A, B, C and G is inferred from the penicillin susceptibility.</p><p><sup>5&nbsp;</sup>insufficient evidence that the species in question is a good target for therapy with the drug. An MIC with a comment but without an accompanying S or R-categorization may be reported.</p></td></tr></tbody></table><p>S=susceptible, R=resistant</p><p><strong><u>Microbiological susceptibility</u></strong></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of cefuroxime axetil in at least some types of infections is questionable.</p><p>Cefuroxime is usually active against the following microorganisms&nbsp;<em>in vitro</em>.</p><table border="1" cellspacing="0" cellpadding="0" style="width:670px"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Staphylococcus aureus</em>&nbsp;(methicillin susceptible)<em>*</em></p><p><em>Streptococcus pyogenes</em></p><p><em>Streptococcus agalactiae</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Haemophilus&nbsp;influenzae</em></p><p><em>Haemophilus parainfluenzae</em></p><p><em>Moraxella catarrhalis</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Spirochaetes:</u></p><p><em>Borrelia&nbsp;burgdorferi</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Microorganisms for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Streptococcus pneumoniae</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Citrobacter freundii</em></p><p><em>Enterobacter aerogenes</em></p><p><em>Enterobacter cloacae</em></p><p><em>Escherichia coli</em></p><p><em>Klebsiella pneumoniae</em></p><p><em>Proteus mirabilis</em></p><p><em>Proteus&nbsp;</em>spp.(other than&nbsp;<em>P. vulgaris</em>)</p><p><em>Providencia</em>&nbsp;spp.</p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive anaerobes:</u></p><p><em>Peptostreptococcus&nbsp;</em>spp.</p><p><em>Propionibacterium&nbsp;</em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative anaerobes:</u></p><p><em>Fusobacterium&nbsp;</em>spp.</p><p><em>Bacteroides&nbsp;</em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Enterococcus faecalis</em></p><p><em>Enterococcus faecium</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Acinetobacter&nbsp;</em>spp.</p><p><em>Campylobacter&nbsp;</em>spp.</p><p><em>Morganella morganii</em></p><p><em>Proteus vulgaris</em></p><p><em>Pseudomonas aeruginosa</em></p><p><em>Serratia&nbsp;marcescens</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative anaerobes:</u></p><p><em>Bacteroides&nbsp;fragilis</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Others:</u></p><p><em>Chlamydia&nbsp;</em>spp.</p><p><em>Mycoplasma</em>&nbsp;spp.</p><p><em>Legionella</em>&nbsp;spp.</p></td></tr></tbody></table><p>* All methicillin-resistant&nbsp;<em>S. aureus</em>&nbsp;are resistant to cefuroxime.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>After oral administration cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolysed in the intestinal mucosa and blood to release cefuroxime into the circulation. Optimum absorption occurs when it is administered shortly after a meal.</p><p>Following administration of cefuroxime axetil tablets peak serum levels (2.9 &micro;g/mL for a 125 mg dose, 4.4 &micro;g/mL for a 250 mg dose, 7.7 &micro;g/mL for a 500 mg dose and 13.6 &micro;g/mL for a 1000 mg dose) occur approximately 2.4 hours after dosing when taken with food. The rate of absorption of cefuroxime from the suspension is reduced compared with the tablets, leading to later, lower peak serum levels and reduced systemic bioavailability (4 to 17% less). Cefuroxime axetil oral suspension was not bioequivalent to cefuroxime axetil tablets when tested in healthy adults and therefore is not substitutable on a milligram-per-milligram basis (see section 4.2).The pharmacokinetics of cefuroxime is linear over the oral dosage range of 125 to 1000 mg. No accumulation of cefuroxime occurred following repeat oral doses of 250 to 500 mg.</p><p><strong><u>Distribution</u></strong></p><p>Protein binding has been stated as 33 to 50% depending on the methodology used. Following a single dose of cefuroxime axetil 500 mg tablet to 12 healthy volunteers, the apparent volume of distribution was 50 L (CV%=28%). Concentrations of cefuroxime in excess of the minimum inhibitory levels for common pathogens can be achieved in the tonsilla, sinus tissues, bronchial mucosa, bone, pleural fluid, joint fluid, synovial fluid, interstitial fluid, bile, sputum and aqueous humor. Cefuroxime passes the blood-brain barrier when the meninges are inflamed.</p><p><strong><u>Biotransformation</u></strong></p><p>Cefuroxime is not metabolised.</p><p><strong><u>Elimination</u></strong></p><p>The serum half-life is between 1 and 1.5 hours. Cefuroxime is excreted by glomerular filtration and tubular secretion. The renal clearance is in the region of 125 to 148 mL/min/1.73 m<sup>2</sup>.</p><p><strong><em><u>Special patient populations</u></em></strong></p><p><strong>Gender</strong></p><p>No differences in the pharmacokinetics of cefuroxime were observed between males and females.</p><p><strong>Elderly</strong></p><p>No special precaution is necessary in the elderly patients with normal renal function at dosages up to the normal maximum of 1 g per day. Elderly patients are more likely to have decreased renal function; therefore, the dose should be adjusted in accordance with the renal function in the elderly (see section 4.2).</p><p><strong>Paediatrics</strong></p><p>In older infants (aged &gt;3 months) and in children, the pharmacokinetics of cefuroxime are similar to that observed in adults.</p><p>There is no clinical trial data available on the use of cefuroxime axetil in children under the age of 3 months.</p><p><strong>Renal impairment</strong></p><p>The safety and efficacy of cefuroxime axetil in patients with renal failure have not been established. Cefuroxime is primarily excreted by the kidneys. Therefore, as with all such antibiotics, in patients with markedly impaired renal function (i.e. C1cr &lt;30 mL/minute) it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion (see section 4.2). Cefuroxime is effectively removed by dialysis.</p><p><strong>Hepatic impairment</strong></p><p>There are no data available for patients with hepatic impairment. Since cefuroxime is primarily eliminated by the kidney, the presence of hepatic dysfunction is expected to have no effect on the pharmacokinetics of cefuroxime.</p><p><strong>PK/PD relationship</strong></p><p>For cephalosporins, the most important pharmacokinetic-pharmacodynamic index correlating with&nbsp;<em>in vivo</em>&nbsp;efficacy has been shown to be the percentage of the dosing interval (%T) that the unbound concentration remains above the minimum inhibitory concentration (MIC) of cefuroxime for individual target species (i.e. %T&gt;MIC).</p><p>&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction and development. No carcinogenicity studies have been performed; however, there is no evidence to suggest carcinogenic potential.</p><p>Gamma glutamyl transpeptidase activity in rat urine is inhibited by various cephalosporins, however the level of inhibition is less with cefuroxime. This may have significance in the interference in clinical laboratory tests in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Inactive Ingredients:</u></strong></p><ol><li>Sodium lauryl sulfate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Kollidon CL (Crospovidone)</li><li>Ac-Di-Sol (Croscarmellose Sodium)</li><li>Aerosil- 200 (Colloidal Silicon Dioxide)</li><li>Primojel (Sodium Starch Glycolate)</li><li>Avicel PH 302 (Microcrystalline Cellulose)</li></ol><p>&nbsp;</p><p><strong><u>Coating Materials:</u></strong></p><ol><li>Hypromellose (Hydroxypropyl Methylcellulose)</li><li>Talc fine powder</li><li>Titanium Dioxide</li><li>Polyethylene Glycol 4000</li><li>Ethanol 95*</li><li>Purified water*</li></ol><p>&nbsp;</p><p>* Evaporates during processing and does not appear in the final product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A positive Coombs&#39; test has been reported during treatment with cephalosporins - this phenomenon can interfere with cross-matching of blood.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months from the date of manufacturing.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C, in a dry place</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 tablets in Alu-Alu blister strips, packed in a printed carton along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None stated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street.
Ras Al Khaimah - United Arab Emirates.
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                17. November. 2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>